Clinical trials on Cuba's Soberana 02 vaccine might start in Mexico

Clinical trials on Cuba's Soberana 02 vaccine might start in Mexico

Health & Medicine

Prensa Latina

Clinical trials on Cuba's Soberana 02 vaccine might start in Mexico, where phase III of the research would be carried out, local media reported on Wednesday. 

Mexican Foreign Secretary Marcelo Ebrard said that the Secretariat of Health is in contact with the Cuban laboratory that is developing the vaccine.

Soberana 02 is a safe antigen, it does not contain the live virus but parts of it, so its administration generates immunity, and it does not cause major reactions and does not need extra refrigeration, as other vaccine candidates in the world.

Mexico is working on its own vaccine against the SARS-CoV-2 coronavirus, which causes Covid-19, and President Andres Manuel Lopez Obrador noted that its name might be Patria (Homeland), Cuba's newspaper Granma reported.

Cuba is doing clinical trials on four vaccine projects against Covid-19, so it might become the first country in Latin America with its own formula against the deadly disease.

Soberana 02 by the Finlay Vaccine Institute (IFV) and Abdala by the Genetic Engineering and Biotechnology Center (CIGB) are the main projects that will go into phase III of clinical trials in March due to the results they have achieved so far.

Meanwhile, Soberana 01, also by the IFV, successfully concluded the first phase of trials and, according to experts, is an ideal boost to the immunity of convalescent patients. 

Mambisa is the only vaccine that is administered nasally, and has proved to be safe with little adverse effects on those who were immunized during the first phase of clinical trials.

Recently, the United Nations Industrial Development Organization (UNIDO) noted that Cuba's vaccine candidates might be potential life savers for developing countries, something that is also in the prospects of the Pan-American Health Organization (PAHO).